[{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Not Applicable"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.33000000000000002,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Emergent BioSolutions","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Chimerix","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"Viral DNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Chimerix","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Brincidofovir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Chimerix","amount2":0.37,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.37,"dosageForm":"Tablet","sponsorNew":"Chimerix \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Chimerix \/ Biomedical Advanced Research and Development Authority"}]

Find Clinical Drug Pipeline Developments & Deals for Brincidofovir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Collaboration with BARDA for the development of TEMBEXA (brincidofovir) has provided the United States government with a second therapeutic option to ensure the federal government’s readiness for a potential smallpox emergency.

                          Brand Name : Tembexa

                          Molecule Type : Small molecule

                          Upfront Cash : $238.0 million

                          August 29, 2022

                          Lead Product(s) : Brincidofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Biomedical Advanced Research and Development Authority

                          Deal Size : $374.5 million

                          Deal Type : Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Chimerix signed a contract agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolution...

                          Brand Name : Tembexa

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 24, 2022

                          Lead Product(s) : Brincidofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Public Health Agency of Canada

                          Deal Size : $25.3 million

                          Deal Type : Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Chimerix expects to promptly provide treatment courses of TEMBEXA (brincidofovir) equivalent to the total value of the procurement contract. Execution of this contract will be the responsibility of Chimerix.

                          Brand Name : Tembexa

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 23, 2022

                          Lead Product(s) : Brincidofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Emergent BioSolutions

                          Deal Size : $9.3 million

                          Deal Type : Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : TEMBEXA (brincidofovir), is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.

                          Brand Name : Tembexa

                          Molecule Type : Small molecule

                          Upfront Cash : $225.0 million

                          May 16, 2022

                          Lead Product(s) : Brincidofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Emergent BioSolutions

                          Deal Size : $325.0 million

                          Deal Type : Acquisition

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 29, 2020

                          Lead Product(s) : Brincidofovir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank